%0 Journal Article
%T Tobramycin (TOBI£¿£¿£¿£¿ or TOBI PODHALER£¿£¿£¿£¿) in Ventilator Associated Pneumonia: An Overview | Insight Medical Publishing
%A Dhilleswara Rao V
%J Open Access statement:
%D 2018
%X Despite the fact that Ventilator Associated Pneumonia (VAP) has a high death rate, it is not yet defined very well. Mortality in patients with lung injury on mechanical ventilation is estimated as 24% in patients 15-19 years and 60% in patients 85 years or older. Very few studies have reported the use of tobramycin (TOBI£¿ or Tobi Podhaler£¿) in VAP management. However, the use of such antibiotics for treatment of VAP is equivocal and no clinical evidences reported. Tobi Podhaler£¿ contains active substance of tobramycin, which is available as capsules (28 mg). Tobi Podhaler£¿ can be used as a hand-held device which suppresses the chronic lung infections caused by P. aeruginosa in patients aged >6 years. The recommended dose is four capsules twice a day in adults and children older than 6 years of age. It can be also used to treat Cystic Fibrosis (CF). This review highlights the advantages of treatment with TOBI (Tobi Podhaler£¿) in VAP patients and also a note on inhaled antibiotics in management of chronic respiratory infections.
%U http://www.ijddr.in/drug-development/tobramycin-tobi-or-tobi-podhaler-in-ventilator-associated-pneumonia-an-overview.php?aid=22327